Construction of an Antithrombotic and Anti-Inflammatory Polyethersulfone Membrane.

Abstract

In addition to being the core factor in thrombosis, thrombin is involved in various inflammatory disease responses, but few studies have examined whether and how it is involved in membrane-related inflammation. In this study, the thrombin inhibitor dabigatran is used to modify a polyethersulfone dialysis membrane. The modified membrane shows good hydrophilic properties and dialysis performance. It reduces the thrombin level in a targeted manner, thereby significantly inhibiting coagulation factor activation (based on the prothrombin time, international normalized ratio, activated partial thromboplastin time and thrombin time) and reducing the fibrinogen level and platelet adhesion. On thromboelastography, it shows excellent dynamic antithrombotic capacity. The modified membrane inhibited membrane-related inflammation by inhibiting the production of the inflammatory mediators C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-1β (IL-1β) via the thrombin/complement C5a pathway. Moreover, it is found to be safe in an in vivo study. Thus, the dabigatran-modified polyethersulfone membrane may reduce dialysis-related complications through its dual antithrombotic and anti-inflammatory effects.

• Authors: Xiao Fu, Ting Lei, Ci Tang, Jie Peng
• Journal: Macromolecular bioscience (Macromol Biosci) Vol. 23 Issue 7 Pg. e2200543 (07 2023) ISSN: 1616-5195 [Electronic] Germany
• PMID: 37057668 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2023 Wiley-VCH GmbH.

Chemical References

• Dabigatran
• Thrombin
• Fibrinolytic Agents
• polyether sulfone
• Anti-Inflammatory Agents

Topics

• Humans
• Dabigatran
• Thrombin (metabolism)
• Fibrinolytic Agents (pharmacology)
• Anti-Inflammatory Agents (pharmacology)
• Inflammation (drug therapy)